Effects of Ocrelizumab on B-cell Tolerance Defect in Relapsing Multiple Sclerosis

NCT04261790 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Multiple Sclerosis, Relapsing-Remitting

Interventions

DRUG: Ocrelizumab

Sponsor

Johns Hopkins University

Collaborators

[object Object]